4Filed Aug 9, 8:00 PM ET

BlossomHill (BLSM) GC Vincent Liptak Buys Shares, Converts Preferred

$BLSM · BlossomHill Therapeutics, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

BlossomHill (BLSM) GC Vincent Liptak Buys Shares, Converts Preferred

What Happened

Vincent Paul Liptak (General Counsel) reported multiple transactions in BlossomHill Therapeutics (BLSM). He purchased 2,500 shares on 2026-08-07 at $15.80 ($39,500) and 2,200 shares on 2026-08-10 at $16.00 ($35,200), for total cash purchases of $74,700. The filing also shows a 46,561-share derivative award (reported 2026-08-06 at $0.00) and related derivative conversions (22,687 shares acquired and 22,687 shares disposed on 2026-08-10). Per the filing footnotes, the derivative activity relates to Series B Preferred Stock that automatically converted into common stock upon the company’s IPO.

Key Details

  • Open-market purchases: 2,500 sh @ $15.80 on 2026-08-07 ($39,500) and 2,200 sh @ $16.00 on 2026-08-10 ($35,200). Total cash outlay: $74,700.
  • Grant/award: 46,561 derivative shares reported 2026-08-06 at $0.00 (derivative instrument).
  • Conversions: two entries on 2026-08-10 for 22,687 shares each (one marked acquired, one marked disposed); footnote F1 explains Series B Preferred automatically converted to common stock at IPO.
  • Vesting: footnote F3 indicates a vesting schedule (1/4 vests Aug 6, 2027; remaining monthly over 36 months).
  • Trust holding: footnote F2 notes the reporting person is co-trustee/co-beneficiary of the Walter T. Liptak Revocable Trust and has voting/dispositive power over Trust securities.
  • The filing does not list a final "shares owned after" total in the summary provided here.

Context

  • The purchases are small-dollar open-market buys (total ~$74.7K), which retail investors often view as a modest insider purchase signal; the derivative grant and conversions reflect IPO-related conversion mechanics rather than a new cash purchase.
  • Derivative entries: the award at $0.00 and subsequent conversions appear tied to preferred-stock-to-common-stock conversion at the IPO (per F1), not a typical option cash exercise. The filing does not indicate any 10b5-1 plan or tax-withholding sale detail.
  • No filing-timeliness issue is indicated in the information provided.